Neurocrine Biosciences Inc
$146.23
-$5.60 (-3.69%)
$146.06Day Range$152.63
Key Statistics
Market Cap
$15.43B
Shares Outstanding
101.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
May 23, 1996
Round Lot
100
Locale
US
Trading Data
Day Open
$152.63
Day High
$152.63
Day Low
$146.06
Volume
2.82M
VWAP
$147.14
Prev Close
$151.83
Transactions
--
Acc. Volume
--
About Neurocrine Biosciences Inc
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 28362,500 employees6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130(858) 617-7600IPO May 23, 1996US / STOCKSActiveWebsite
Identifiers
- CIK
- 0000914475
- Composite FIGI
- BBG000GJS7C1
- Share Class FIGI
- BBG001S8W4X9
- Ticker Root
- NBIX
- SIC Code
- 2836
About Neurocrine Biosciences Inc (NBIX) Stock
Neurocrine Biosciences Inc (NBIX) closed the 2026-09-18 session at $146.23, down 3.69% versus the previous close (-5.60). The stock opened at $152.63 and traded between $146.06 and $152.63 during that session. Session trading volume was 2.8M shares. The volume-weighted average price (VWAP) is $147.14.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Neurocrine Biosciences Inc has a market capitalization of $15.43 billion. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. NBIX is listed on the XNAS exchange. The company employs approximately 2,500 people. Neurocrine Biosciences Inc is headquartered in SAN DIEGO, CA. The recorded listing date is 1996-05-23.
On this page you can find market NBIX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.